A number of other research analysts have also recently commented on the company. Jefferies Financial Group raised their target price on PureTech Health from GBX 245 ($3.20) to GBX 255 ($3.33) and gave the company a buy rating in a research note on Friday, January 4th. Liberum Capital restated a buy rating on shares of PureTech Health in a research note on Friday, October 26th. Five research analysts have rated the stock with a buy rating, The company presently has an average rating of Buy and an average target price of GBX 268.75 ($3.51).
LON PRTC traded down GBX 11.05 ($0.14) on Thursday, hitting GBX 166.95 ($2.18). The company’s stock had a trading volume of 23,346 shares, compared to its average volume of 71,917. PureTech Health has a 52-week low of GBX 111.50 ($1.46) and a 52-week high of GBX 183.50 ($2.40).
PureTech Health plc, a clinical-stage biopharma company, focuses on developing medicines for diseases caused by dysfunctions in the nervous, gastrointestinal, and immune systems. The company is developing a microbiome immune system drug-discovery platform and drug candidates for immune-mediated diseases; and products to induce weight loss and enhance glycaemic control through an orally administered capsule.
Recommended Story: Day Trading
Receive News & Ratings for PureTech Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PureTech Health and related companies with MarketBeat.com's FREE daily email newsletter.